Our analysis revealed a trend towards elevated expression of CD69, KIR, and CD52, alongside diminished expression of CD226, NKG2D, and CD62L in patients who contracted COVID-19, when contrasted with those with T2D or control subjects. This evidence concerns the gene CD52 and type 2 diabetes mellitus.